Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 171

Results For "CCO"

1761 News Found

Mindpeers launches on-demand behavioural healthcare platform
Healthcare | August 04, 2021

Mindpeers launches on-demand behavioural healthcare platform

It is designed to tackle mental health issues


PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
Policy | August 03, 2021

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya

The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Drug Approval | August 02, 2021

Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients

Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine


PI Industries acquires API business of Ind Swift Laboratories
News | August 02, 2021

PI Industries acquires API business of Ind Swift Laboratories

Turnover of API division of ISLL stood at Rs 856.58 crore


Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Biotech | August 02, 2021

Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Balaxi Pharmaceuticals Q1 revenue increases by 12%
News | July 20, 2021

Balaxi Pharmaceuticals Q1 revenue increases by 12%

The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY


Lonza extends collaboration with Biopharma company
News | July 19, 2021

Lonza extends collaboration with Biopharma company

As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies